ASTX-6660 is under clinical development by Astex Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ASTX-6660’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ASTX-6660 overview

ASTX-660 (AT-IAP) is under development for the treatment of solid tumors, lymphomas such as diffuse large B-cell lymphoma, triple negative breast cancer (TNBC), glioblastoma, recurrent head, and neck squamous cell carcinoma, laryngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, breast cancer, cervical carcinoma, relapsed or refractory peripheral T-cell lymphoma (PTCL), relapsed or refractory cutaneous T-cell lymphoma (CTCL), relapsed or refractory adult T-cell leukemia/lymphoma (ATLL), angioimmunoblastic T-cell lymphoma, anaplastic large-cell lymphoma (ALCL) and melanoma. The drug candidate is administered through the oral route. It is a dual antagonist of XIAP and cIAP1. The drug is developed based on Pyramid technology. It was also under development for the treatment of leukemia, relapsed and refractory (R/R) acute myeloid leukemia.

Astex Pharmaceuticals overview

Astex Pharmaceuticals, a subsidiary of Otsuka Holdings Co Ltd, is a drug discovery and development company with a focus on cancer and central nervous system (CNS) diseases. The company’s proprietary fragment-based drug discovery platform, Pyramid delivers high-quality and customized drug leads across a variety of therapeutic targets and disease areas. Its pipeline product and programs include DNMT inhibitor, Oral DNMT inhibitor, dual IAP antagonist, oral murine double minute 2 (MDM2) antagonist and extracellular signal-related protein kinases inhibitor. Astex Pharmaceuticals is also advancing several of its compounds into clinical trials in collaboration with Novartis, AstraZeneca, GSK, and Janssen. The company operates as a subsidiary of Otsuka Pharmaceutical Co Ltd. Astex Pharmaceuticals is headquartered in Pleasanton, California, the US.

For a complete picture of ASTX-6660’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.